Focus: Parabilis Medicines is a Cambridge-based biotechnology company pioneering cell-penetrating miniproteins for oncology, currently advancing a Phase 1/2 program. The company recently completed a $770.5M IPO in June 2026, establishing public-market validation for its novel platform technology.
Profile data last refreshed 20h ago · AI intelligence enriched 3w ago
Stable — net -3 jobs in 30d
3 added, 6 removed. Backfill posture.
Parabilis is a high-risk, high-reward opportunity for scientists and operators who thrive in capital-efficient startup environments and want equity upside tied to a novel platform's clinical validation.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Parabilis Medicines
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Parabilis Medicines's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Under CEO Mathai Mammen, Cambridge Biotech Parabilis Medicines Pursues $450 Million IPO - INDIA New England News
Under CEO Mathai Mammen, Cambridge Biotech Parabilis Medicines Pursues $450 Million IPO INDIA New England News
Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy? - The Motley Fool
Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy? The Motley Fool
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO - BioSpace
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO BioSpace
Parabilis Sets Biotech IPO Record - The Medicine Maker
Parabilis Sets Biotech IPO Record The Medicine Maker
StockWatch: Parabilis Medicines Makes Wall Street History with $770.5M IPO - Genetic Engineering and Biotechnology News
StockWatch: Parabilis Medicines Makes Wall Street History with $770.5M IPO Genetic Engineering and Biotechnology News
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock? - The Motley Fool
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock? The Motley Fool
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo